ARS Pharmaceuticals, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 3.64M | $29.27M | 0.00% | Added+13.1% | 2026-03-31 |
| ThirdPoint | activist | 1.00M | $8.03M | 0.39% | Added+79.8% | 2026-03-31 |
| FidelityFMR | fundamental | 342.0K | $2.75M | 0.00% | Trimmed-14.3% | 2026-03-31 |
| DEShaw | quant | 11.9K | $95.34K | 0.00% | Trimmed-55.2% | 2026-03-31 |
| TRowePrice | fundamental | 40.8K | $328 | 0.00% | Added+20.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.53 | — | — |
| 2026-05-15 | -0.53 | -0.61 | -14.02% |
| 2026-03-09 | -0.48 | -0.42 | +12.50% |
| 2025-11-10 | -0.49 | -0.52 | -6.12% |
| 2025-08-13 | -0.51 | -0.46 | +10.68% |
| 2025-05-14 | -0.36 | -0.35 | +3.45% |
| 2025-03-20 | -0.12 | 0.51 | +534.04% |
| 2024-11-13 | -0.14 | -0.20 | -42.86% |
| 2024-08-06 | -0.11 | -0.13 | -13.04% |
| 2024-05-09 | -0.11 | -0.11 | — |
| 2024-03-21 | -0.12 | -0.07 | +44.00% |
| 2023-11-09 | -0.18 | -0.16 | +11.11% |
| 2023-08-10 | -0.16 | -0.18 | -9.09% |
| 2023-05-15 | -0.15 | -0.16 | -3.23% |
| 2023-03-23 | -0.12 | -0.09 | +25.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SPRY | +5.96% | +0.33% | -22.15% | -37.28% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | +2.99% | +5.16% | -18.70% | -49.90% |